Carnitine Inborn Errors of Metabolism.
Level 5 - mechanism / opinion, no new human data
Narrative review of biochemical mechanisms and clinical phenotypes without systematic methodology.
PubMed 31500110 · doi:10.3390/molecules24183251
What was done
This narrative review summarizes carnitine metabolism, physiological homeostasis, and the biochemical pathways involving endogenous synthesis, renal reabsorption, and cellular transport via OCTN2. It outlines inborn errors affecting carnitine biosynthesis, transport, and the mitochondrial carnitine-acylcarnitine cycle (CPT I, CACT, CPT II), along with secondary causes of carnitine deficiency, their clinical presentations, diagnosis, and treatment options.
What was found
In non-vegetarians, approximately 75% of carnitine is acquired through the diet and 25% through endogenous synthesis from lysine and methionine. Inborn errors impairing carnitine biosynthesis, transport, or mitochondrial β-oxidation shuttling characteristically produce hypoketotic hypoglycemia, cardiomyopathy or myopathy, and liver disease. The abstract provides no specific patient counts or numerical diagnostic/therapeutic outcome metrics.
Why it matters
It provides a consolidated overview of the genetic and metabolic disruptions in fatty acid oxidation pathways, aiding in the clinical recognition and differential diagnosis of inborn carnitine disorders.
Limits
The publication is an expert narrative review without systematic search protocols, meta-analytic pooling, or risk of bias assessment. No original empirical data, sample sizes, or quantitative treatment comparisons are reported in the abstract.
Cited by
- supports GBB (gamma-butyrobetaine) is the biochemical precursor to L-carnitine.
- supports Carnitine and acetyl-L-carnitine are required in the mitochondria for fatty acid oxidation.